Aurobindo Pharma Ltd Share Price
(AUROPHARMA)
₹1257.8▲0.88%
as on 04:01PM, 24 Apr 2025
Day's Low
Day's High
52 Week's Low
52 Week's High
Returns % | |
1 Month Return | + 5.26 % |
3 Month Return | + 6.93 % |
1 Year Return | + 13.99 % |
Market Stats | |
Previous Close | ₹1,246.80 |
Open | ₹1,246.80 |
Volume | 13.38L |
Upper Circuit | ₹1,371.40 |
Lower Circuit | ₹1,122.20 |
Market Cap | ₹73,699.36Cr |
P/E Ratio
21.05
PEG Ratio
1.68
Market Cap
₹73,699.36 Cr
P/B Ratio
3.24
EPS
54.09
Dividend Yield
0.41
Sector
Pharmaceuticals
ROE
10.35
based on 28 analysts
78.57%
Buy
7.14%
Hold
14.29%
Sell
Based on 28 analysts offering long term price targets for Aurobindo Pharma. An average target of ₹1470.82
Source: S&P Global Market Intelligence
Aurobindo Pharma price forecast by 28 analysts
Upside of16.94%
High
₹1930
Target
₹1470.82
Low
₹1140
Aurobindo Pharma target price ₹1470.82, a slight upside of 16.94% compared to current price of ₹1257.8. According to 28 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Aurobindo Pharma revenue growth forecast
Expected growth rate Q1, FY2027:28.22%
Forecast
Actual
Including amortisation and stock based compensations
Aurobindo Pharma EPS growth forecast
EPS estimate Q1, FY2027:50.79%
Forecast
Actual
Source: S&P Global Market Intelligence
Aurobindo Pharma Stock Shows Strong Momentum - 22 Apr, 2025
Aurobindo Pharma Gains USFDA Approval for Rivaroxaban - 12 Apr, 2025
Aurobindo Pharma Faces FDA Scrutiny Amid Trial Success - 11 Apr, 2025
Aurobindo Pharma Completes Phase 1 Trials for BP16 - 10 Apr, 2025
Aurobindo Pharma Faces Tariff Threats Amid Drug Success - 09 Apr, 2025
Aurobindo Pharma Gains EU Approval Amid Profit Decline - 07 Apr, 2025
Aurobindo Pharma Secures EU Approval for Dyrupeg - 05 Apr, 2025
Aurobindo Pharma Shares Plummet Amid Tariff Concerns - 04 Apr, 2025
Aurobindo Pharma Shares Surge After Tariff Exemption - 03 Apr, 2025
Aurobindo Pharma Faces Potential Tariff Challenges - 02 Apr, 2025
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Revenue Rich
Revenue is up for the last 10 quarters, 5.79K Cr → 8.13K Cr (in ₹), with an average increase of 3.7% per quarter
Profit Spike
Netprofit is up for the last 2 quarters, 817.38 Cr → 845.81 Cr (in ₹), with an average increase of 3.4% per quarter
Price Rise
In the last 7 days, AUROPHARMA stock has moved up by 6.4%
MF Holding Up
Mutual Funds have increased holdings from 17.81% to 18.21% in Mar 2025 quarter
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 143.9% return, outperforming this stock by 48.8%
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 55.3% return, outperforming this stock by 40.3%
Promoter Holding Unchanged
Promoters holdings remained unchanged at 51.82% of holdings in Mar 2025 quarter
FII Holding Down
Foreign Institutions have decreased holdings from 16.29% to 15.33% in Mar 2025 quarter
Retail Holding Down
Retail Investor have decreased holdings from 6.69% to 6.61% in Mar 2025 quarter
Investors | Holdings % | FY Quarter | 3M change |
---|---|---|---|
Promoter Holdings | 51.82% | 0.00 | |
Foreign Institutions | 15.33% | 0.00 | |
Mutual Funds | 18.21% | 0.00 | |
Retail Investors | 6.61% | 0.00 | |
Others | 8.03% | 0.00 |
Aurobindo Pharma in the last 5 years
Lowest (6.73x)
March 23, 2020
Today (21.05x)
April 24, 2025
Industry (54.50x)
April 24, 2025
Highest (27.59x)
December 21, 2023
Aurobindo Pharma Ltd’s net profit fell -9.66% since last year same period to ₹845.81Cr in the Q3 2024-2025. On a quarterly growth basis, Aurobindo Pharma Ltd has generated 3.48% jump in its net profits since last 3-months.
Read More about Earnings ResultsIn the quarter ending December 2023, Aurobindo Pharma Ltd has declared dividend of ₹1.50 - translating a dividend yield of 0.36%.
Read More about DividendsBearish
Neutral
Bullish
Aurobindo Pharma Ltd is currently in a Bullish trading position according to technical analysis indicators.
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
---|---|---|---|---|---|---|
BUY | ₹73,699.36 Cr | 19.69% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
BUY | ₹15,129.56 Cr | -2.79% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
HOLD | ₹88,573.75 Cr | 32.73% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
BUY | ₹63,877.50 Cr | 15.4% | 0.53 | NA | NA | |
BUY | ₹49,398.80 Cr | 20.4% | 0.56 | ₹589 Cr | ₹3,453 Cr |
Organisation | Aurobindo Pharma |
Headquarters | Hyderabad |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Aurobindo Pharma Ltd share price today stands at ₹1257.8, Open: ₹1246.8, Previous Close: ₹1246.8, High: ₹1278.6, Low: ₹1239.8, 52 Week High: ₹1592, 52 Week Low: ₹1010.
Today's traded volume of Aurobindo Pharma Ltd(AUROPHARMA) is 13.38L.
Today's market capitalisation of Aurobindo Pharma Ltd(AUROPHARMA) is ₹73699.36Cr.
Aurobindo Pharma Ltd (AUROPHARMA) share price is ₹1257.8. It is down -20.99% from its 52 Week High price of ₹1592
Aurobindo Pharma Ltd (AUROPHARMA) share price is ₹1257.8. It is up 24.53% from its 52 Week Low price of ₹1010